



Span Divergent Ltd.
(Formerly Span Diagnostics Ltd.)
9th Floor, Rajhans Bonista,
Behind Ram Chowk, Ghod Dod Road,
Surat - 395 007, Gujarat, India
Phone: +91 261 266 32 32
E-Mail: contact@span.in

Date: August 11, 2026

**To,
Listing Compliance Department
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Tower, 25th Floor
Dalal Street,
Mumbai – 400 001**

Scrip Code: 524727

Subject: Outcome of the Board Meeting – August 11, 2026

Respected Sir,

We are pleased to inform you that at the meeting of Board of Directors held on Tuesday, August 11, 2026, the Board of Directors has approved the Un-audited Integrated Financial Results (Both Standalone & Consolidated) of the Company for the First Quarter and Three months ended June 30, 2026, of the Current Financial Year 2026 - 27 as recommended by the Audit Committee along with Limited Review Report of the Statutory Auditors of the Company, M/s. Y B Desai & Associates, Surat.

A copy of the said Un-audited Financial Results (Standalone and Consolidated) containing disclosures required under Regulation 30, 33 and other provisions of the Listing Regulations as applicable along with the Limited Review Report by the Statutory Auditor of the company is enclosed.

The Board meeting commenced at 11:15 (IST) and concluded at 16:30 (IST).

You are therefore requested to take the above information on records.

Thanking You.

Yours faithfully,

For Span Divergent Limited

**Viral Desai
Managing Director
DIN 00029219**

CIN: L74999GJ1980PLC003710

www.span.in

Span Divergent Limited

(Formerly known as Span Diagnostics Limited)


Regd. Office : 9th Floor, 902-904, Rajhans Bonista, Behind Ram Chowk Temple, Ghod Dod Road, Surat-395007

CIN:L74999GJ1980PLC003710 Website: www.span.in

Statement of unaudited Financial Result for the quarter ended June 30, 2026.

(Rs in Lakhs)

Sr. No.	Particulars	Standalone Results			
		Three Months			Year ended 31 March 2026
		Quarter ended 30 June 2026	Quarter ended 31 March 2026	Quarter ended 30 June 2025	
		Unaudited	Unaudited	Unaudited	
1	Income from operations				
	Other Operating Income	13.45	35.66	38.45	146.64
	Other income	17.38	12.25	26.48	75.78
	Total income	30.83	47.91	64.93	222.42
2	Expenses				
	Employee benefit expense	26.39	36.39	26.92	122.76
	Finance costs	0.42	0.46	-	2.16
	Depreciation and amortisation expense	5.75	6.53	6.28	25.80
	Other expenses	14.00	8.58	7.99	40.24
	Total expenses	46.56	51.96	41.19	190.96
3	Profit / (Loss) before exceptional items and tax (1-2)	(15.73)	(4.05)	23.74	31.46
4	Exceptional items	(13.20)	(7.60)	(19.00)	(41.10)
5	Profit/(Loss) before tax (3-4)	(2.53)	3.55	42.74	72.56
6	Tax expense:				
	- Current tax	-	-	-	-
	- Deferred tax	1.69	(1.66)	1.07	(0.08)
7	Profit/(Loss) for the period after tax (5-6)	(4.22)	5.21	41.67	72.64
8	Other comprehensive income				
	Item that will not be reclassified to Profit or Loss (Consisting of re-measurement of net defined benefit liabilities)	(0.63)	5.84	(0.18)	5.29
	Income tax relating to items that will not be reclassified to Profit or Loss	0.14	(1.36)	0.05	(1.21)
9	Total comprehensive income for the year (7+8)	(4.71)	9.69	41.54	76.72
10	Paid-up equity share capital (Face value of Rs. 10/- each)	726.32	726.32	546.17	726.32
11	Other Equity	-	-	-	3,396.15
12	Weightage Average No of Paid-up Equity Shares	72,63,228	54,81,489	54,61,747	54,81,489
	Earnings per equity share for profit from operation attributable to owners of the entity:				
13	Basic earnings per share	(0.06)	0.09	0.76	1.33
14	Diluted earnings per share	(0.06)	0.09	0.76	1.33



[Handwritten signature]

Note :-

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 11, 2026.
- 2 Other Operating Income comprises of Interest on fluctuating capital provided by the Company to its LLP subsidiaries and management fees income which is based on the revenue earned by subsidiaries during the quarter.
- 3 In case of subsidiary:
 - a) Aranya Consulting and Biotech LLP, w.e.f May19, 2026 (Formerly, Aranya Agri Biotech LLP) had accumulated losses of Rs. 1494 Lakhs till March 31 2026 and loss of Rs.0.69 Lakhs in the current year, up to June 30, 2026.
 - (b) Biospan Scientific LLP had accumulated losses of Rs.157 Lakhs as at 31st March 2019, resulting in substantial erosion of the net worth of the LLP. Hence the Management had decided to impair the investment and Rs. 183 Lakhs were provided in the books of the Company and was treated as an exceptional item during the year 2018-19. Notwithstanding the above, the financial results of the LLP has been prepared on going concern basis as Management is exploring the possibilities to revive the LLP on its own or by entering in to business tie-ups and it endeavours to be able to establish profitable operation.
 - (c) Biospan Contamination Control Solutions Pvt. Ltd had accumulated losses of Rs.742 Lakhs till June 30, 2026. As on that date the subsidiary Company's total liabilities exceeded its total assets by Rs. 752 Lakhs. Notwithstanding the above, the financial results of the subsidiary Company has been prepared on going concern basis as Management believes that the company would be able to establish profitable operation and the losses incurred is attributable to factors of temporary nature. Further, Management is confident that with appropriate product introductions, the Company will achieve adequate revenue and negative net worth would turn positive in short term horizon.
- 4 Previous periods figures have been regrouped and rearranged wherever necessary.
- 5 The financial results of the Company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under Section 133 of the Companies Act, 2013 read with the relevant rules of the Companies (Indian Accounting Standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards)(Amendment) Rules, 2016.
- 6 The above financial results are also available on the Company's website www.span.in and BSE Limited's website www.bseindia.com.

For Span Divergent Limited




Viral Desai

Managing Director

DIN: 00029219

Place : Surat

Date : August 11, 2026




B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC – APPLICABLE (ANNEXURE ATTACHED)

C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES – NOT APPLICABLE, NO DEFAULT

D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half-yearly filings i.e., 2nd and 4th quarter) – NOT APPLICABLE

E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONGWITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter) - NOT APPLICABLE



A handwritten signature in blue ink, consisting of stylized, cursive letters.

STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED

INSTITUTIONS PLACEMENT ETC.

Statement of Deviation / Variation in utilization of funds raised								
Name of listed entity	Span Divergent Limited							
Mode of Fund Raising	Preferential Issue							
Date of Raising Funds	March 28, 2026 i.e. Date of allotment							
Amount Raised	INR 579.36 Lakhs							
Report filed for Quarter ended	June 30, 2026							
Monitoring Agency	Not applicable							
Monitoring Agency Name, if applicable	Not Applicable							
Is there a Deviation / Variation in use of funds raised	No							
If yes, whether the same is pursuant to change in terms of a contractor objects, which was approved by the shareholders	Not Applicable							
If Yes, Date of shareholder Approval	Not Applicable							
Explanation for the Deviation / Variation	-							
Comments of the Audit Committee after review	-							
Comments of the auditors, if any	-							
Objects for which funds have been raised and where there has been a deviation, in the following table								
Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any		
Procurement of Raw Cashew Nut (RCN) Inventory (2 - 3 Months upfront)	NA	500.00 Lakhs	0.00	372.96 lakhs	0.00	Refer Note 1		
Restart and Ramp-up Costs (Commissioning & Operational Mobilisation)	NA	50.00 Lakhs	0.00	50.00 Lakhs	0.00			
Selective Refurbishment for Productivity and Quality	NA	29.36 Lakhs	0.00	29.36 Lakhs	0.00			
Note 1: There is no deviation or variation in the utilisation of the preferential issue proceeds. The unutilized amount of ₹127.04 lakhs will be utilized towards the stated objects of the issue.								


Deviation or variation could mean:

- (a) Deviation in the objects or purposes for which the funds have been raised or
- (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or
- (c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc

FOR SPAN DIVERGENT LIMITED

Viral Desai

VIRAL DESAI
MANAGING DIRECTOR
DIN 00029219



Span Divergent Limited

(Formerly known as Span Diagnostics Limited)

Regd. Office : 9th Floor, 902-904, Rajhans Bonista, Behind Ram Chowk Temple, Ghod Dod Road, Surat-395007

CIN: L74999GJ1980PLC003710 Website: www.span.in

Statement of Consolidated unaudited Results for the Quarter ended June 30, 2026.

(Rs. In Lakhs)

Sr. No.	Particulars	Consolidated Results			
		Quarter ended 30 June 2026	Quarter ended 31 March 2026	Quarter ended 30 June 2025	Year ended 31 March 2026
		Unaudited	Unaudited	Unaudited	Audited
1	Income from operations				
	Sale of Traded Products/Services	88.63	457.53	96.23	1,689.50
	Other Operating Income	13.25	6.95	10.80	32.96
	Other income	28.32	14.59	72.18	128.62
	Total income	130.20	479.07	179.21	1,851.08
2	Expenses				
	Cost of materials consumed	-	-	-	-
	Purchases of stock-in-trade	478.01	439.28	423.99	1,630.37
	Changes in inventories of work-in-progress, stock-in-trade and finished goods	(402.69)	12.77	(354.23)	(72.85)
	Employee benefit expense	46.95	56.38	51.16	214.57
	Finance costs	13.67	12.23	11.92	43.26
	Depreciation and amortisation expense	24.38	30.15	27.23	117.25
	Other expenses	84.45	41.35	52.60	208.97
	Total expenses	244.77	592.16	212.67	2,141.57
3	Profit / (Loss) before tax and Exceptional items (1-2)	(114.57)	(113.09)	(33.46)	(290.49)
4	Exceptional items	-	-	(19.00)	-
5	Profit/(Loss) before tax (3-4)	(114.57)	(113.09)	(14.46)	(290.49)
6	Tax expense:				
	- Current tax	-	-	-	-
	- Deferred tax	4.25	(1.32)	2.55	4.23
7	Profit/(Loss) for the period after tax (5-6)	(118.82)	(111.77)	(17.01)	(294.72)
	Profit for the year attributable to:				
	(a) Owners of the Company	(105.18)	(96.13)	(9.83)	(250.15)
	(b) Non Controlling Interest	(13.64)	(15.64)	(7.18)	(44.57)
		(118.82)	(111.77)	(17.01)	(294.72)
8	Other comprehensive income				
	Item that will not be reclassified to Profit or Loss (Consisting of re-measurement of net defined benefit liabilities)	(1.10)	3.43	(0.005)	3.42
	Income tax relating to items that will not be reclassified to Profit or Loss	0.31	(1.27)	0.005	(1.26)
	Other comprehensive income	(0.79)	2.16	(0.01)	2.16
	Other comprehensive income attributable to:				
	(a) Owners of the Company	(0.77)	1.94	0.04	2.10
	(b) Non Controlling Interest	(0.019)	0.22	(0.05)	0.06
		(0.79)	2.16	(0.01)	2.16
9	Total comprehensive income for the year (7+8)	(119.61)	(109.61)	(17.02)	(292.56)
	Total comprehensive income attributable to:				
	(a) Owners of the Company	(105.99)	(93.75)	(9.89)	(247.94)
	(b) Non Controlling Interest	(13.62)	(15.86)	(7.12)	(44.62)
		(119.61)	(109.61)	(17.02)	(292.56)
10	Paid-up equity share capital (Face value of Rs. 10/- each)	726.32	726.32	546.17	726.32
11	Other Equity	-	-	-	759.61
	Earnings per equity share for profit from operation				
12	Basic earnings per share *	(1.64)	(2.02)	(0.31)	(5.38)
13	Diluted earnings per share *	(1.64)	(2.02)	(0.31)	(5.38)

* For the period only and not annualised



[Handwritten signature]

Note :-

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 11, 2026.
- 2 The financial results of the Company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under Section 133 of the Companies Act, 2013 read with the relevant rules of the Companies (Indian Accounting Standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards)(Amendment) Rules, 2016.
- 3 In case of subsidiary:
 - a) Aranya Consulting and Biotech LLP, w.e.f May19, 2026 (Formerly, Aranya Agri Biotech LLP) had accumulated losses of Rs. 1494 Lakhs till March 31 2026 and loss of Rs.0.69 Lakhs in the current year, up to June 30, 2026.
 - (b) Biospan Scientific LLP had accumulated losses of Rs.157 Lakhs as at 31st March 2019, resulting in substantial erosion of the net worth of the LLP. Hence the Management had decided to impair the investment and Rs. 183 Lakhs were provided in the books of the Company and was treated as an exceptional item during the year 2018-19. Notwithstanding the above, the financial results of the LLP has been prepared on going concern basis as Management is exploring the possibilities to revive the LLP on its own or by entering in to business tie-ups and it endeavours to be able to establish profitable operation.
 - (c) Biospan Contamination Control Solutions Pvt. Ltd had accumulated losses of Rs.742 Lakhs till June 30, 2026. As on that date the subsidiary Company's total liabilities exceeded its total assets by Rs. 752 Lakhs. Notwithstanding the above, the financial results of the subsidiary Company has been prepared on going concern basis as Management believes that the company would be able to establish profitable operation and the losses incurred is attributable to factors of temporary nature. Further, Management is confident that with appropriate product introductions, the Company will achieve adequate revenue and negative net worth would turn positive in short term horizon.
- 4 Previous quarters and periods figures have been regrouped and rearranged wherever necessary.

For, Span Divergent Limited



Viral Desai

Managing Director

DIN: 00029219

Place : Surat

Date : August 11, 2026




6. Consolidated Segment Revenue, Results Assets and Liability as at June 30, 2026.

(Rs. In Lakhs)

Sr. No.	Particulars	Three Months			Year ended 31 March 2026
		Quarter ended 30 June 2026	Quarter ended 31 Mar 2026	Quarter ended	
		Unaudited	Unaudited	Unaudited	
1	Segment Revenue				
	- Cashew processing	35.41	379.56	15.27	1,367.57
	- Tissu Culture	-	2.09	-	24.94
	- Trading	67.14	81.30	111.34	364.16
	Gross Revenue from Operations from Segments	102.55	462.95	126.61	1,756.67
	Less : Inter Segment Revenue	-	-	-	-
	Net Revenue from Operations from Segments	102.55	462.95	126.61	1,756.67
2	Segment Results				
	Profit / (Loss) before Interest and tax				
	- Cashew processing	(81.93)	(75.54)	(65.91)	(269.22)
	- Tissu Culture	-	-	-	-
	- Trading	(19.91)	(33.71)	(11.25)	(73.89)
	- Unallocable Income over expenses like (Including HO)	(12.74)	(3.85)	62.70	52.62
	Total Profit / (Loss) before Tax	(114.58)	(113.10)	(14.46)	(290.49)
3	Segment Assets				
	- Cashew processing	1,698.78	926.85	1,215.56	926.85
	- Tissu Culture	68.76	69.94	70.59	69.94
	- Trading	388.64	456.97	376.41	456.97
	- Unallocable	6,322.03	1,436.48	4,086.19	1,436.48
	Total Assets	8,478.21	2,890.24	5,748.75	2,890.23
4	Segment Liability				
	- Cashew processing	1,155.07	336.51	621.42	336.51
	- Tissu Culture	9.66	10.23	9.75	10.23
	- Trading	1,035.60	1,038.61	873.99	1,038.61
	- Unallocable	2,204.28	522.18	569.07	522.18
	Total Liability	4,404.61	1,907.53	2,074.23	1,907.53

For Span Divergent Limited

Place : Surat
Date : August 11, 2026



Viral Desai
Managing Director
DIN: 00029219



Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report

To the Board of Directors of


Span Divergent Ltd.

1. We have reviewed the accompanying statement of unaudited standalone financial results of Span Divergent Limited (the "Company") for the quarter ended June 30, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Y. B. Desai and Associates
Chartered Accountants
Firm Registration No. 102368W



Mayank Y. Desai
Partner

Membership No. :- 108310
UDIN : 26108310ZBKCYO7014

Date :- 11th August, 2026

Place :- Surat

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report

To the Board of Directors of

Span Divergent Ltd.

1. We have reviewed the accompanying Statement of unaudited Consolidated Financial Results of **Span Divergent Limited** (the "Holding Company") and its subsidiary (the Holding Company and its subsidiary together referred to as "the Group") for the quarter ended June 30, 2026 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular Issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable

4. The Statement includes the results of the following entities:

Parent Company:

- i) Span Divergent Limited



Subsidiary:


- Dryfruit Factory LLP
- Aranya Consulting and Biotech LLP
- Biospan Scientific LLP
- Biospan Contamination Control Solutions Pvt Ltd

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Y. B. Desai and Associates

Chartered Accountants

Firm Registration No. 102368W




Mayank Y. Desai

Partner

Membership No. :- 108310

UDIN: 26108310RPDMEF1865



Date :- 11th August, 2026

Place :- Surat